Newsome Park Strategies is thrilled to announce its partnership with Ur24 Technology, a manufacturer of the revolutionary TrueClr active external catheter system. A recent study conducted by Ur24 Technology, in collaboration with a diverse group of 41 patients aged 20 to 82, has yielded promising results for the TrueClr catheter system.

The study, a Prospective Blinded Evaluation, assessed the catheter system’s effectiveness in removing urine from the bladder without causing tissue injury, focusing on patient satisfaction metrics. The participants, comprising 21 males and 20 females, utilized the TrueClr catheter system in both inpatient and outpatient settings over a one- to two-week period. The evaluation encompassed various aspects, including urinary collection, skin condition, comfort, duration of use, and ease of use.
The study revealed that the TrueClr catheter was highly effective in safely removing urine, with no reported instances of skin irritation among the participants. Impressively, the survey data reflected significant satisfaction across all categories:

Internal catheters are accountable for 80% of urinary tract infections in US hospitals, contributing to an estimated annual expenditure of $6.2 billion and causing nearly 13,000 deaths. The study’s recommendations indicate that TrueClr has the potential to replace both external and internal catheters in diverse clinical scenarios, offering a viable solution to the significant challenges posed by Catheter Associated Urinary Tract Infections (CAUTIs). Our collaboration with TrueClr aligns perfectly with Newsome Park Strategies’ values, as we advocate for a catheter system that not only prioritizes patient satisfaction but also addresses the critical issue of UTIs in the hospital setting. Furthermore, by providing a cost-effective and highly reimbursed alternative to existing options in the market, we are committed to making a meaningful impact on healthcare practices. This partnership exemplifies the essence of Newsome Park Strategies’ DNA.